Droloxifene (3-hydroxytamoxifen) has membrane antioxidant ability: potential relevance to its mechanism of therapeutic action in breast cancer.

doi:10.1016/0304-3835(92)90281-Y

Paper

DOI: 10.1016/0304-3835(92)90281-Y

Droloxifene (3-hydroxytamoxifen) has membrane antioxidant ability: potential relevance to its mechanism of therapeutic action in breast cancer.

Published Sep 14, 1992 · H. Wiseman, C. Smith, B. Halliwell

Cancer letters

Q1 SJR score

Citations

Influential Citations

Full textSemantic Scholar

Abstract

Abstract hidden due to publisher request; this does not indicate any issues with the research. Click the full text link above to read the abstract and view the original source.

In Vitro Study

Study Snapshot

Droloxifene (3-hydroxytamoxifen) exhibits membrane antioxidant ability, potentially contributing to its antiproliferative action in breast cancer by reducing lipid peroxidation.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Full text analysis coming soon...

References

DOI: 10.1016/0925-4439(92)90038-O

The structural mimicry of membrane sterols by tamoxifen: evidence from cholesterol coefficients and molecular-modelling for its action as a membrane anti-oxidant and an anti-cancer agent.

Tamoxifen shares structural similarity with cholesterol, ergosterol, and 17--oestradiol, suggesting its anti-oxidant properties may be related to membrane stabilization and anti-cancer effects.

1992·46citations·Helen Wiseman et al.·Biochimica et biophysica acta

Biochimica et biophysica acta

DOI: 10.1093/JNCI/83.20.1450

Potential role of tamoxifen in prevention of breast cancer.

Tamoxifen shows potential as a chemopreventive agent for breast cancer in women at increased risk, with well-tolerated side effects and potential health benefits.

1991·392citations·S. Nayfield et al.·Journal of the National Cancer Institute

Journal of the National Cancer Institute

DOI:

Distribution of tamoxifen and its metabolites in rat and human tissues during steady-state treatment.

Tamoxifen and its metabolites are efficiently retained and slowly washed out in various human tissues, with high concentrations in liver and lung, and pancreas, pancreatic tumor, and brain metastases.

1991·377citations·E. Lien et al.·Cancer research

Cancer research

DOI: 10.1016/0006-2952(91)90448-E

Influence of di- and tri-phenylethylene estrogen/antiestrogen structure on the mechanisms of protein kinase C inhibition and activation as revealed by a multivariate analysis.

Di- and tri-phenylethylene derivatives with basic amino side-chains inhibit protein kinase C activity, while 1,1-bis-(p-hydroxyphenyl) ethylene moiety stimulate it, with the latter affecting the enzyme's catalytic domain.

1991·33citations·E. Bignon et al.·Biochemical pharmacology

Biochemical pharmacology

DOI: 10.1038/bjc.1991.276

Can we prevent breast cancer?

Tamoxifen and gestodene show potential in preventing breast cancer, while low-fat diets remain unproven and screening is inconclusive.

1991·28citations·M. Baum et al.·British Journal of Cancer

British Journal of Cancer

DOI: 10.1016/0006-2952(91)90131-N

Identification of the cytochrome P450 IIIA family as the enzymes involved in the N-demethylation of tamoxifen in human liver microsomes.

The cytochrome P450 IIIA family enzymes are involved in the oxidative demethylation of tamoxifen in human liver microsomes, leading to the DMT metabolite.

1991·192citations·Françoise Jacolot et al.·Biochemical pharmacology

Biochemical pharmacology

DOI:

Decreased P-glycoprotein in a tamoxifen-tolerant breast carcinoma model.

Prolonged Tamoxifen exposure in breast cancer cells leads to decreased P-glycoprotein expression, potentially increasing their vulnerability to other chemotherapeutic modalities.

1991·9citations·J. Kellen et al.·Anticancer research

Anticancer research

DOI: 10.1038/348699A0

A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas

Stromelysin-3, a novel metalloproteinase gene, may play a role in the progression of epithelial malignancies by degrading the extracellular matrix in breast carcinoma stromal cells.

1990·1158citations·P. Basset et al.·Nature

Nature

DOI: 10.1016/0014-5793(90)81341-K

Mechanism of inhibition of lipid peroxidation by tamoxifen and 4‐hydroxytamoxifen introduced into liposomes

Tamoxifen and 4-hydroxytamoxifen effectively inhibit lipid peroxidation in liposomes, potentially due to structural mimicry of sterols as membrane stabilizers against lipid peroxidation.

1990·43citations·Helen Wiseman et al.·FEBS Letters

FEBS Letters

Citations

DOI: 10.1177/1934578X221119912

Revisiting the Effect of 3 Sesquiterpenoids From Conocephalum conicum (Snake Liverwort) on Rat Spleen Lymphocyte Viability and Membrane Functioning

Sesquiterpenoids from Conocephalum conicum (Snake Liverwort) may have anticancer potential through changes in cell membrane function and leakage/inhibition of LDH in unaltered immune cells.

2022·2citations·S. Filipović et al.·Natural Product Communications

Natural Product Communications

DOI: 10.1016/j.freeradbiomed.2010.11.006

Nonesterified cholesterol content of lysosomes modulates susceptibility to oxidant-induced permeabilization.

Lysosomal nonesterified cholesterol/sterol content modulates susceptibility to reactive oxygen species-induced lysosomal membrane permeabilization, potentially by acting as an alternative target for oxidants and reducing damage to other lysosomal membrane lipids and proteins.

2011·35citations·J. Reiners et al.·Free radical biology & medicine

Free radical biology & medicine

DOI: 10.1007/s10456-006-9029-x

Quantitative comparison of the inhibitory effects of GW5638 and tamoxifen on angiogenesis in the cornea pocket assay

GW5638 effectively inhibits angiogenesis in the cornea as tamoxifen, but is less toxic and has minimal effects on body weight.

2006·9citations·Sheng Tong et al.·Angiogenesis

Angiogenesis

DOI: 10.1016/J.AB.2004.12.023

Effect of anti-inflammatory drugs on splenocyte membrane fluidity.

Anti-inflammatory drugs indomethacin, diclofenac, piroxicam, and tenoxicam increase splenocyte membrane fluidity in a concentration-dependent manner, with tenoxicam being the most effective.

2005·34citations·H. Ferreira et al.·Analytical biochemistry

Analytical biochemistry

DOI: 10.1016/J.VPH.2004.01.005

Chronic effects of toremifene on the vasculature of menopause-induced rats.

Chronic toremifene treatment improves cardiovascular performance in menopause-induced rats by reversing endothelial dysfunction and decreasing vascular resting tone.

2003·6citations·Jorge González-Pérez et al.·Vascular pharmacology

Vascular pharmacology